Bio Green Med Solution, Inc.

Regulatory Filings • Jul 31, 2025

CORRESP 1 filename1.htm

CYCLACEL PHARMACEUTICALS, INC.

Level 10, Tower 11, .Avenue 5, The Horizon

Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia

July 31, 2025

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

via EDGAR

RE:
Registration
Statement on Form S-1
Filed:
July 30, 2025
Securities
Act File No.: 333-288911

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form S-1 (File No. 333-288911), filed on July 30, 2025, so that it will become effective at 5:00 p.m. (Eastern time) on August 4, 2025, or as soon as practicable thereafter.

If you have any questions, or require any additional information, please do not hesitate to email Debbie Klis, the Registrant’s outside counsel at Rimon P.C. via email at debbie.klis@rimonlaw.com or by phone on 202-935-3390.

| Very
truly yours, | |
| --- | --- |
| Cyclacel
Pharmaceuticals, Inc. | |
| By: | /s/
Datuk Dr. Doris Wong |
| | Datuk
Dr. Doris Wong |
| | Chief
Executive Officer |

Field: Page; Sequence: 1; Options: Last

Field: /Page